2,4,7-trimethyloct-6-en-1-ol

Endpoint summary

Key value for chemical safety assessment

Skin sensitisation

Link to relevant study records

Reference

Reference 1

Endpoint:

skin sensitisation: in chemico

Type of information:

experimental study

Adequacy of study:

key study

Study period:

2017

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Qualifier:

according to guideline

Guideline:

OECD Guideline 442C (In Chemico Skin Sensitisation: Direct Peptide Reactivity Assay (DPRA))

GLP compliance:

no

Remarks:

GLP equivalent

Type of study:

direct peptide reactivity assay (DPRA)

Details on the study design:

The Direct peptide reactivity Assay (DPRA) is an in chemico test to determine the reactivity of test a
substance towards peptides.
This assay has been validated for a broad range of low-molecular weight chemicals and it was found
to detect reactive skin sensitizers from a broad range of so called applicability domains, i.e.
chemicals reacting with proteins by different mechanisms. It was validated by ECVAM and proposed
to be used as part of an integrated approach for testing and assessment (IATA).

The test substance was dissolved in acetonitrile and mixed with a Cysteine- and a
Lysine-containing peptide according to the standard operating procedure of the DPRA. One study
with three replicates was conducted. After 24 h incubation time, peptide depletion induced by was determined by HPLC-UV.

Key result

Parameter:

other: Average depletion Cys-and Lys-peptide

Value:

0.5

Vehicle controls validity:

valid

Negative controls validity:

valid

Positive controls validity:

valid

Interpretation of results:

GHS criteria not met

Conclusions:

The result of the DPRA assay should be used as part of an integrated approach for testing and assessment (IATA). A parallel test in the KeratinoSens™ assay may indicate whether congruent results are obtained by both test methods. According to a detailed analysis on large set of chemicals, two congruent results in these two tests give a good prediction of the sensitizer hazard [3-5] particularly when predicting human data, while an additional test in a dendritic cell line assessing expression of surface markers may be needed in case of discordant results.
The test substance was non-reactive and classified into the MINIMAL reactivity class according to the prediction model. It is therefore considered a non-sensitizer according to the prediction model of the DPRA.

Executive summary:

The test substance was not reactive in the DPRA assay and can be considered a non-sensitiser in this assay.

Reference 2

Endpoint:

skin sensitisation: in vitro

Type of information:

experimental study

Adequacy of study:

key study

Study period:

2017

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Qualifier:

according to guideline

Guideline:

OECD Guideline 442D (In Vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method)

GLP compliance:

no

Remarks:

GLP equivalence

Type of study:

activation of keratinocytes

Details on the study design:

The KeratinoSensTM assay is a cell-based assay with a reporter cell line to detect potential skin
sensitizers by their ability to induce the Nrf2-response.
This assay has been validated for a broad range of low-molecular weight chemicals and it was found
to respond to skin sensitizers from a broad range of so called applicability domains, i.e. chemicals
reacting with proteins by different mechanisms. It was validated by ECVAM and proposed to be
used as part of an integrated approach for testing and assessment (IATA).

The test substance was dissolved in DMSO and tested according to the standard
operating procedure of the KeratinoSensTM assay at 12 concentrations in three repetitions, each
time in three replicates. After 48 h incubation time, luciferase induction and cellular viability at each
of the concentrations were determined.

Positive control results:

Cinnamic aldehyde was run in all three repetitions. Here the detailed results for this positive control
are reported in Table 8 and Figure 5. Cinnamic aldehyde needs to be positive for a run to be
accepted (i.e. induction > 1.5 fold). This was the case in all three repetitions. The induction at 64 μM
and the EC 1.5 for cinnamic aldehyde were also calculated. The targets are: (i) Average induction in
the three replicates for cinnamic aldehyde at 64 μM should be between 2 and 8, and (ii) the EC 1.5
value should be between 7 μM and 30 μM. At least one of these two numerical criteria must be met
in order to accept a repetition. In the experiments performed here both criteria were fulfilled in all
three repetitions. Thus all three repetitions were valid for the positive control.

Key result

Run / experiment:

other: 1

Parameter:

other: IMAX (fold induction)

Value:

1.21

Vehicle controls validity:

valid

Negative controls validity:

valid

Positive controls validity:

valid

Interpretation of results:

GHS criteria not met

Conclusions:

The result of the KeratinoSens™ assay should be used as part of an integrated approach for testing
and assessment (IATA)[9]. A parallel test in the DPRA may indicate whether congruent results are
obtained by both test methods. According to a detailed analysis on large set of substances, two
congruent results in these two tests give a good prediction of the sensitizer hazard [5, 7, 18], in
particular when comparing against human data, while an additional test in a dendritic cell line
assessing expression of surface markers may be needed in case of discordant results.
In all three repetitions, no induction of the luciferase above the threshold of 1.5 was noted.
According to the prediction model of the KeratinoSens™ assay, the test substance is rated as nonsensitizer.
This conclusion is also clearly supported by the analysis of the dose-response curve in
Figure 4 with overall no induction of the luciferase reporter gene to be observed.

Executive summary:

No induction was seen in the Keratinosens^TM assay and the substance can be considered as non sensitising in this assay.

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed (not sensitising)

Justification for classification or non-classification

The result of the KeratinoSens™ and DPRA assays should be used as part of an integrated approach for testing

and assessment (IATA). According to a detailed analysis on large set of substances, two

congruent results in these two tests give a good prediction of the sensitizer hazard, in

particular when comparing against human data, while an additional test in a dendritic cell line

assessing expression of surface markers may be needed in case of discordant results.

In both assays, this substance showed no evidence of reactivity and is not sensitising. Therefore it can be considered with confidence that this substance is not a skin sensitiser in humans.